{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:59:18Z","timestamp":1793411958443,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Polycythemia vera (PV) is characterized by clonal hematopoietic stem or progenitor cells with constitutively active somatic mutation(s) in the <jats:italic>Janus kinase 2<\/jats:italic> gene. Phlebotomy (Phl) and aspirin are often used alone for low-risk PV patients. However, data from the Low-PV study demonstrated that Phl and aspirin may not be adequate for patients. Therapeutic intervention with disease-modifying treatment appears to be beneficial for patients with PV regardless of the risk category. Ropeginterferon alfa-2b (ropeg) is a novel interferon-based therapy with favorable dosing schedules. A higher starting-dose (250\u00a0\u00b5g) regimen with simpler dose titrations was found to have a potent disease-modifying effect with respect to inducing a molecular response. PARADIGM-PV is a randomized, phase 4 study with the primary goal of assessing the efficacy of ropeg at this dosing regimen in alleviating Phl-dependence in both low- and high-risk patients with PV. The secondary endpoints include complete hematologic response, molecular response, symptom improvement, maintenance of median hematocrit (Hct) values\u2009&lt;\u200945% without disease progression, and safety. Patients will be randomized equally to receive either ropeg every two weeks or to continue their current treatment with Phl or other cytoreductive agents (e.g., hydroxyurea, other interferons, or ruxolitinib) as applicable. All patients will receive Phl if their Hct values are elevated to \u226545% according to the National Comprehensive Cancer Network guidelines. The study will enroll approximately 70 patients internationally, including patients in the US. This study will provide new efficacy data, measured as the ability of ropeg to reduce Phl eligibility and modify the disease.\n<\/jats:p>","DOI":"10.1007\/s00277-025-06185-5","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:24:45Z","timestamp":1736749485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera"],"prefix":"10.1007","author":[{"given":"Abdulraheem","family":"Yacoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Abu-Zeinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsewang","family":"Tashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Da\u2019na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichung Joe","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Zagrijtschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Yen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"2","key":"6185_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y","journal-title":"Blood Cancer J"},{"issue":"12","key":"6185_CR2","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2021) Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 35(12):3339\u20133351. https:\/\/doi.org\/10.1038\/s41375-021-01401-3","journal-title":"Leukemia"},{"issue":"9464","key":"6185_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. TLancet 365(9464):1054\u20131061. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9","journal-title":"TLancet"},{"key":"6185_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148. https:\/\/doi.org\/10.1038\/nature03546","journal-title":"Nature"},{"key":"6185_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorder. N Engl J Med 352:1779\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"issue":"4","key":"6185_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"issue":"12","key":"6185_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 95(12):1599\u20131613. https:\/\/doi.org\/10.1002\/ajh.26008","journal-title":"Am J Hematol"},{"key":"6185_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"issue":"23","key":"6185_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.5184.5184","volume":"126","author":"S Fazal","year":"2015","unstructured":"Fazal S, Miller CB, Mascarenhas JO et al (2015) Phlebotomy frequency and quality of life and productivity in patients with polycythemia vera: results from the MPN landmark survey in the United States. Blood 126(23):5184","journal-title":"Blood"},{"key":"6185_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R (2018) Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia 32:2105\u20132116. https:\/\/doi.org\/10.1038\/s41375-018-0207-9","journal-title":"Leukemia"},{"issue":"2S\u20132","key":"6185_CR11","doi-asserted-by":"publisher","first-page":"676S","DOI":"10.1093\/jn\/131.2.676S","volume":"131","author":"JD Haas","year":"2001","unstructured":"Haas JD, Brownlie T (2001) Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutrition 131(2S\u20132):676S-688S. https:\/\/doi.org\/10.1093\/jn\/131.2.676S","journal-title":"J Nutrition"},{"key":"6185_CR12","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology, Myeloproliferative Neoplasms. Version 1; 2024. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed 09 Feb 2024"},{"key":"6185_CR13","unstructured":"U.S. Food and Drug Administration (US FDA) website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202192s028lbl.pdf. Accessed 19 June 2024"},{"key":"6185_CR14","doi-asserted-by":"publisher","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al. (2015) Ropeginterferon alfa-2b, a novel IFNa-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126(15):1762\u20131769. 1182\/blood-2015\u201304\u2013637280.\u00a0https:\/\/doi.org\/10.1182\/blood-2015-04-637280","DOI":"10.1182\/blood-2015-04-637280"},{"key":"6185_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A (2021) Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig 41:391\u2013404. https:\/\/doi.org\/10.1007\/s40261-021-01026-5","journal-title":"Clin Drug Investig"},{"key":"6185_CR16","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/bcp.15176","volume":"88","author":"YW Huang","year":"2022","unstructured":"Huang YW, Qin A, Fang J et al (2022) Novel long acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol 88:2396\u20132407. https:\/\/doi.org\/10.1111\/bcp.15176","journal-title":"Br J Clin Pharmacol"},{"key":"6185_CR17","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1007\/s12325-021-01863-y","volume":"38","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai CY, Tsai CW et al (2021) Pharmacokinetics and pharmacodynamics of novel long acting ropeginterferon alfa-2b in healthy Chinese subjects. Adv Ther 38:4756\u20134770. https:\/\/doi.org\/10.1007\/s12325-021-01863-y","journal-title":"Adv Ther"},{"key":"6185_CR18","unstructured":"European Medicines Agency. \u201cBesremi: ropeginterferon alfa-2b.\u201d https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besremi#authorisation-details-section. Accessed 16 Nov 2022"},{"key":"6185_CR19","unstructured":"U.S. Food and Drug Administration website. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=9583405d-53a0-49dc-88eb-5e6384ebabcb&type=display. Accessed 19 June 2024."},{"issue":"3","key":"6185_CR20","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196-208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4","journal-title":"Lancet Haematol"},{"issue":"4","key":"6185_CR21","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9(4):e301-311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1","journal-title":"Lancet Haematol"},{"issue":"3","key":"6185_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","volume":"102","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, Valone F, Gupta S (2023) Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol 102(3):571\u2013581. https:\/\/doi.org\/10.1007\/s00277-023-05089-6","journal-title":"Ann Hematol"},{"issue":"19","key":"6185_CR23","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124(19):3021\u20133023. https:\/\/doi.org\/10.1182\/blood-2014-07-591610","journal-title":"Blood"},{"key":"6185_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","volume":"126","author":"T Barbui","year":"2015","unstructured":"Barbui T, Masciulli A, Marfisi MR et al (2015) White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126:560\u2013561. https:\/\/doi.org\/10.1182\/blood-2015-04-638593","journal-title":"Blood"},{"issue":"12","key":"6185_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","volume":"104","author":"A Ferrari","year":"2019","unstructured":"Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, Vannucchi AM, Barbui T (2019) Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica 104(12):2391\u20132399. https:\/\/doi.org\/10.3324\/haematol.2019.221234","journal-title":"Haematologica"},{"issue":"3","key":"6185_CR26","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V et al (2021) Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 8(3):e175\u2013e184. https:\/\/doi.org\/10.1016\/S2352-3026(20)30373-2","journal-title":"Lancet Haematol"},{"key":"6185_CR27","doi-asserted-by":"publisher","unstructured":"Barbui T, Vannucchi AM, De Stefano V et al. (2023) Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid 2(6). https:\/\/doi.org\/10.1056\/EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335"},{"issue":"2","key":"6185_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","volume":"103","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, De Stefano V et al (2024) Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. Ann Hematol 103(2):437\u2013442. https:\/\/doi.org\/10.1007\/s00277-023-05577-9","journal-title":"Ann Hematol"},{"key":"6185_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1173467","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A (2023) An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol 13:1173467. https:\/\/doi.org\/10.3389\/fonc.2023.1173467","journal-title":"Front Oncol"},{"issue":"9","key":"6185_CR30","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"35","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T et al (2021) Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia 35(9):2592\u20132601. https:\/\/doi.org\/10.1038\/s41375-021-01183-8","journal-title":"Leukemia"},{"issue":"10","key":"6185_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2023) Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia 37(10):2129\u20132132. https:\/\/doi.org\/10.1038\/s41375-023-02008-6","journal-title":"Leukemia"},{"issue":"12","key":"6185_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00277-014-2205-y","volume":"93","author":"BL Stein","year":"2014","unstructured":"Stein BL, Moliterno AR, Tiu RV (2014) Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol 93(12):1965\u20131976. https:\/\/doi.org\/10.1007\/s00277-014-2205-y","journal-title":"Ann Hematol"},{"key":"6185_CR33","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2V617F allele burden in polycythemia vera: burden of proof. Blood 141:1934\u20131942. https:\/\/doi.org\/10.1182\/blood.2022017697","journal-title":"Blood"},{"key":"6185_CR34","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R et al (2023) Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol 41:3534\u20133544. https:\/\/doi.org\/10.1200\/JCO.22.01935","journal-title":"J Clin Oncol"},{"issue":"6","key":"6185_CR35","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T et al (2007) European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446\u20132452. https:\/\/doi.org\/10.1182\/blood-2006-08-042515","journal-title":"Blood"},{"issue":"2","key":"6185_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/AJH.21593","volume":"85","author":"V De Stefano","year":"2010","unstructured":"De Stefano V, Za T, Rossi E et al (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85(2):97\u2013100. https:\/\/doi.org\/10.1002\/AJH.21593","journal-title":"Am J Hematol"},{"issue":"3","key":"6185_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/J.1365-2141.2007.06674.X","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138(3):354\u2013358. https:\/\/doi.org\/10.1111\/J.1365-2141.2007.06674.X","journal-title":"Br J Haematol"},{"issue":"Suppl","key":"6185_CR38","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/01.HS9.0000847116.74895.d8","volume":"6","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Mesa R, Burke JM et al (2022) P1062: A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera: an analysis of data from the REVEAL study. Hemasphere 6(Suppl):952\u2013953. https:\/\/doi.org\/10.1097\/01.HS9.0000847116.74895.d8","journal-title":"Hemasphere"},{"key":"6185_CR39","doi-asserted-by":"publisher","first-page":"1109866","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J (2023) An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future. Front Oncol 13:1109866. https:\/\/doi.org\/10.3389\/fonc.2023.1109866","journal-title":"Front Oncol"},{"issue":"2","key":"6185_CR40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","volume":"120","author":"CE Huang","year":"2021","unstructured":"Huang CE, Wu YY, Hsu CC et al (2021) Real-world experience with ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms. J Formos Med Assoc 120(2):863\u2013873. https:\/\/doi.org\/10.1016\/j.jfma.2020.08.021","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"6185_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A et al (2023) A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol 12(1):55. https:\/\/doi.org\/10.1186\/s40164-023-00415-0","journal-title":"Exp Hematol Oncol"},{"issue":"Supplement 1","key":"6185_CR42","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1182\/blood-2023-180922","volume":"142","author":"H Gill","year":"2023","unstructured":"Gill H, Au L, Leung GMK et al (2023) Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low\/intermediate-1 risk myelofibrosis: durable responses and evidence of disease modification. Blood 142(Supplement 1):4562. https:\/\/doi.org\/10.1182\/blood-2023-180922","journal-title":"Blood"},{"key":"6185_CR43","doi-asserted-by":"publisher","unstructured":"Suo S, Fu R, Qin A et al (2024) Effective management of polycythemia vera with ropeginterferon alfa-2b. J Hematol 13(1\u20132):12\u201322. https:\/\/doi.org\/10.14740\/jh1245","DOI":"10.14740\/jh1245"},{"issue":"suppl 1","key":"6185_CR44","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1182\/blood-2023-184431","volume":"142","author":"SE Lee","year":"2023","unstructured":"Lee SE, Yoon SS, Yang DH et al (2023) Single-arm, open-label, multicenter study to assess molecular response of P1101 therapy in patients with polycythemia vera and elevated hematocrit: results from 12-month core study. Blood 142(suppl 1):4575. https:\/\/doi.org\/10.1182\/blood-2023-184431","journal-title":"Blood"},{"key":"6185_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s44276-024-00076-4","volume":"2","author":"K Kirito","year":"2024","unstructured":"Kirito K, Qin A, Suo S et al (2024) Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia. BJC Rep 2:51. https:\/\/doi.org\/10.1038\/s44276-024-00076-4","journal-title":"BJC Rep"},{"issue":"6","key":"6185_CR46","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","volume":"90","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Li Y et al (2024) Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Br J Clin Pharmacol 90(6):1493\u20131502. https:\/\/doi.org\/10.1111\/bcp.16043","journal-title":"Br J Clin Pharmacol"},{"key":"6185_CR47","unstructured":"JAKAFI\u2122 (ruxolitinib) tablets [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202192s028lbl.pdf. Accessed 16 Sept 2024."},{"issue":"8","key":"6185_CR48","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395\u20131398. https:\/\/doi.org\/10.1182\/blood-2013-03-488098","journal-title":"Blood"},{"key":"6185_CR49","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International working group for myelofibrosis research and treatment. Leukemia 22:437\u2013438. https:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"key":"6185_CR50","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6185_CR51","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"Suppl 1","key":"6185_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/liv.13006","volume":"36","author":"F Invernizzi","year":"2016","unstructured":"Invernizzi F, Vigan\u00f2 M, Grossi G, Lampertico P (2016) The prognosis and management of inactive HBV carriers. Liver Int 36(Suppl 1):100\u2013104. https:\/\/doi.org\/10.1111\/liv.13006","journal-title":"Liver Int"},{"key":"6185_CR53","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s00277-024-05912-8","volume":"103","author":"G Abu-Zeinah","year":"2024","unstructured":"Abu-Zeinah G, Qin A, Gill H et al (2024) A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early\/lower-risk primary myelofibrosis. Ann Hematol 103:3573\u20133583. https:\/\/doi.org\/10.1007\/s00277-024-05912-8","journal-title":"Ann Hematol"},{"issue":"8","key":"6185_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N et al (2024) Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med 390(8):723\u2013735. https:\/\/doi.org\/10.1056\/NEJMoa2308809","journal-title":"N Engl J Med"},{"key":"6185_CR55","doi-asserted-by":"publisher","first-page":"TPS6592 -TPS659","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6592","volume":"42","author":"A Banker","year":"2024","unstructured":"Banker A, Pettit K, Shatzel J et al (2024) VERIFY: a randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV). J Clin Oncol 42:TPS6592\u2013TPS6592. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS6592","journal-title":"J Clin Oncol"},{"issue":"7","key":"6185_CR56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/sim.1688","volume":"23","author":"YH Chen","year":"2004","unstructured":"Chen YH, DeMets DL, Lan KK (2004) Increasing the sample size when the unblinded interim result is promising. Stat Med 23(7):1023\u20131038. https:\/\/doi.org\/10.1002\/sim.1688","journal-title":"Stat Med"},{"key":"6185_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cct.2015.12.007","volume":"47","author":"WJ Shih","year":"2016","unstructured":"Shih WJ, Li G, Wang Y (2016) Methods for flexible sample-size design in clinical trials: likelihood, weighted, dual test, and promising zone approaches. Contemp Clin Trial 47:40\u201348. https:\/\/doi.org\/10.1016\/j.cct.2015.12.007","journal-title":"Contemp Clin Trial"},{"key":"6185_CR58","doi-asserted-by":"publisher","unstructured":"Shih WJ, Aisner J (2021) Statistical design, monitoring, and analysis of clinical trials: principles and methods, 2nd edn. Chapman and Hall\/CRC. https:\/\/doi.org\/10.1201\/9781003176527","DOI":"10.1201\/9781003176527"},{"issue":"5","key":"6185_CR59","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"10","key":"6185_CR60","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-022-04963-z","volume":"101","author":"A Triguero","year":"2022","unstructured":"Triguero A, Pedraza A, P\u00e9rez-Encinas M et al (2022) Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann Hematol 101(10):2231\u20132239. https:\/\/doi.org\/10.1007\/s00277-022-04963-z","journal-title":"Ann Hematol"},{"key":"6185_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12185-024-03804-1","volume":"120","author":"K Shimoda","year":"2024","unstructured":"Shimoda K, Qin A, Komatsu N, Kirito K (2024) Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b. Int J Hematol 120:151\u2013156. https:\/\/doi.org\/10.1007\/s12185-024-03804-1","journal-title":"Int J Hematol"},{"key":"6185_CR62","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clinthera.2024.03.005","volume":"46","author":"A Qin","year":"2024","unstructured":"Qin A (2024) Mechanism of action of ropeginterferon alfa-2b in polycythemia vera treatment. Clin Thera 46:439\u2013440. https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.005","journal-title":"Clin Thera"},{"key":"6185_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2402649","author":"A Qin","year":"2024","unstructured":"Qin A (2024) A plain language summary about a cell cycle-based, new surveillance mechanism against cancer. Future Oncol. https:\/\/doi.org\/10.1080\/14796694.2024.2402649","journal-title":"Future Oncol"},{"issue":"1","key":"6185_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jfma.2023.08.023","volume":"23","author":"CC Lo","year":"2024","unstructured":"Lo CC, Chuang WL, Kuo HT, Chen WM, Qin A, Tsai CY, Huang YW, Chen CY (2024) A therapeutic dose and its pharmacokinetics of ropeginterferon alfa-2b for hepatitis C treatment. J Formos Med Assoc 23(1):55\u201361. https:\/\/doi.org\/10.1016\/j.jfma.2023.08.023","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"6185_CR65","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/jgh3.12825","volume":"6","author":"CY Chen","year":"2022","unstructured":"Chen CY, Chuang WL, Qin A et al (2022) A phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. JGH Open 6(11):782\u2013791. https:\/\/doi.org\/10.1002\/jgh3.12825","journal-title":"JGH Open"},{"key":"6185_CR66","unstructured":"PEGINTRON (Peginterferon alfa-2b) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103949s5313lbl.pdf. Accessed 19 June 2024"},{"key":"6185_CR67","unstructured":"PEGASYS (Peginterferon alfa-2a) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103964s5204lbl.pdf. Accessed 19 June 2024."},{"key":"6185_CR68","unstructured":"INTRON A (Interferon alfa-2b, recombinant) [package insert]. U.S. food and drug administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103132s5202lbl.pdf. Accessed 19 June 2024."},{"key":"6185_CR69","unstructured":"PharmaEssentia Corp (2024) Periodic safety update report number 5. Period Covered by Report: 15-Feb-2023 to 14-Feb-2024"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06185-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:24:50Z","timestamp":1736749490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06185-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":69,"alternative-id":["6185"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06185-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approvalThe study follows the principles of the Declaration of Helsinki for all human experimental investigations. The study is expected be approved by the appropriate institutional review board or ethnic committee of the participating clinical centers or hospitals. Informed consent will be obtained from all participating patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial is registered at clinicaltrials.gov. The registration identifier is NCT06290765.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}},{"value":"A Yacoub: consultancy: Incyte, CTI Pharma (SOBI), PharmaEssentia, Pfizer, Novartis, Servier, ABBVIE, Karyopharm Therapeutics, GSK, Blueprint Medicine, Apellis, Gilead, Notable Labs, and Protagonist; Research funding: CTI Pharma (SOBI), Stemline Therapeutics.G Abu-Zeinah: no competing interests to declare;A Qin: working for PharmaEssentia and serving as the company\u2019s chief medical officer;T Tashi: Blueprint (Consultancy, research funding and speakers bureau), PharmaEssentia (Consultancy, research funding and speakers bureau), Cogent (Consultancy, research funding), CITI Biopharma (Consultancy, research funding and speakers bureau), Italfarmaco (Consultancy), and Telios. Research funding (Consultancy).W Da\u2019na: no competing interests to declare;W Shih: serving as a consultant of PharmaEssentia;O Zagrijtschuk: working for PharmaEssentia USA;C Tsai: working for PharmaEssentia Corporation;N Komatsu: Served as a board member of and received funding for medical writing and article processing charges from PharmaEssentia Japan K.K. and received research funding from Meiji Seika Pharma Co., Ltd. and consulting fees from Torii Pharmaceutical Co., Ltd.;R Mesa: Consultant (Honoraria) over past 3\u00a0years: Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology, Telios; Research Support: Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys, Sierra;H Gill: Consulting fees\/Speaker fees from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Advisory board for Abbvie, Bristol Myers Squibb, GSK, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Celgene, MSD, Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}